1
|
Siddique AR, Bhagwat GS. Erythrocytes Nanoparticle Delivery: A Boon for Targeting Tumor. Adv Pharm Bull 2024; 14:132-146. [PMID: 38585450 PMCID: PMC10997934 DOI: 10.34172/apb.2023.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Revised: 01/14/2023] [Accepted: 04/24/2023] [Indexed: 04/09/2024] Open
Abstract
Although nanoparticles (NPs) have many advantages as drug delivery systems, their poor stability in circulation, premature drug release, and nonspecific uptake in non-target organs have prompted biomimetic approaches to camouflage nano vehicles using natural cell membranes. Among them, which are extensively studied in erythrocytes, are the most abundant circulating blood cells. They are specially used for biomimetic coating on artificial NPs due to their excellent properties of good biocompatibility, biodegradability, non-immunogenicity, and long-term blood circulation. Erythrocyte-mimicking nanoparticles (EM-NPs) are prepared by combining nanoparticle cores with naturally derived erythrocyte (red blood cell or RBC) membranes. Compared with conventional nanosystems, EM-NPs hold the preferable characteristics of prolonged blood circulation time and immune evasion. In this review, the biomimetic platform of erythrocyte membrane-coated NPs is described in various aspects, with particular focus placed on the coating mechanism, preparation methods, characterization method, and recent advances in the biomedical applications of EM-NPs concerning cancer and targeted delivery.
Collapse
Affiliation(s)
| | - Geeta Sameer Bhagwat
- Pharmaceutics Department, DY Patil University School of Pharmacy, Sector-7, Nerul, Navi Mumbai 400706, India
| |
Collapse
|
2
|
Berikkhanova K, Taigulov E, Bokebaev Z, Kusainov A, Tanysheva G, Yedrissov A, Seredin G, Baltabayeva T, Zhumadilov Z. Drug-loaded erythrocytes: Modern approaches for advanced drug delivery for clinical use. Heliyon 2024; 10:e23451. [PMID: 38192824 PMCID: PMC10772586 DOI: 10.1016/j.heliyon.2023.e23451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 12/04/2023] [Accepted: 12/04/2023] [Indexed: 01/10/2024] Open
Abstract
Scientific organizations worldwide are striving to create drug delivery systems that provide a high local concentration of a drug in pathological tissue without side effects on healthy organs in the body. Important physiological properties of red blood cells (RBCs), such as frequent renewal ability, good oxygen carrying ability, unique shape and membrane flexibility, allow them to be used as natural carriers of drugs in the body. Erythrocyte carriers derived from autologous blood are even more promising drug delivery systems due to their immunogenic compatibility, safety, natural uniqueness, simple preparation, biodegradability and convenience of use in clinical practice. This review is focused on the achievements in the clinical application of targeted drug delivery systems based on osmotic methods of loading RBCs, with an emphasis on advancements in their industrial production. This article describes the basic methods used for encapsulating drugs into erythrocytes, key strategic approaches to the clinical use of drug-loaded erythrocytes obtained by hypotonic hemolysis. Moreover, clinical trials of erythrocyte carriers for the targeted delivery are discussed. This article explores the recent advancements and engineering approaches employed in the encapsulation of erythrocytes through hypotonic hemolysis methods, as well as the most promising inventions in this field. There is currently a shortage of reviews focused on the automation of drug loading into RBCs; therefore, our work fills this gap. Finally, further prospects for the development of engineering and technological solutions for the automatic production of drug-loaded RBCs were studied. Automated devices have the potential to provide the widespread production of RBC-encapsulated therapeutic drugs and optimize the process of targeted drug delivery in the body. Furthermore, they can expedite the widespread introduction of this innovative treatment method into clinical practice, thereby significantly expanding the effectiveness of treatment in both surgery and all areas of medicine.
Collapse
Affiliation(s)
- Kulzhan Berikkhanova
- Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Kabanbay Batyr 53, Astana, 010000, Kazakhstan
| | - Erlan Taigulov
- University Medical Center, Nazarbayev University, Astana, 010000, Kazakhstan
- Astana Medical University, Astana, 010000, Kazakhstan
| | - Zhanybek Bokebaev
- Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Kabanbay Batyr 53, Astana, 010000, Kazakhstan
- Astana Medical University, Astana, 010000, Kazakhstan
| | - Aidar Kusainov
- Semey State Medical University, Semey, 071400, Kazakhstan
| | | | - Azamat Yedrissov
- Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Kabanbay Batyr 53, Astana, 010000, Kazakhstan
| | - German Seredin
- Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Kabanbay Batyr 53, Astana, 010000, Kazakhstan
| | - Tolkyn Baltabayeva
- Scientific-Production Center of Transfusiology, Astana, 010000, Kazakhstan
| | - Zhaxybay Zhumadilov
- Departament of Surgery, School of Medicine, Nazarbayev University, Kabanbay Batyr 53, Astana, 010000, Kazakhstan
| |
Collapse
|
3
|
Li D. Role of Spectrin in Endocytosis. Cells 2022; 11:cells11152459. [PMID: 35954302 PMCID: PMC9368487 DOI: 10.3390/cells11152459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 08/02/2022] [Accepted: 08/06/2022] [Indexed: 11/16/2022] Open
Abstract
Cytoskeletal spectrin is found in (non)erythroid cells. Eukaryotic endocytosis takes place for internalizing cargos from extracellular milieu. The role of spectrin in endocytosis still remains poorly understood. Here, I summarize current knowledge of spectrin function, spectrin-based cytoskeleton and endocytosis of erythrocytes, and highlight how spectrin contributes to endocytosis and working models in different types of cells. From an evolutionary viewpoint, I discuss spectrin and endocytosis in a range of organisms, particularly in plants and yeast where spectrin is absent. Together, the role of spectrin in endocytosis is related to its post-translational modification, movement/rearrangement, elimination (by proteases) and meshwork fencing.
Collapse
Affiliation(s)
- Donghai Li
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China
| |
Collapse
|
4
|
Nowak-Jary J, Machnicka B. Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications. J Nanobiotechnology 2022; 20:305. [PMID: 35761279 PMCID: PMC9235206 DOI: 10.1186/s12951-022-01510-w] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 06/07/2022] [Indexed: 12/05/2022] Open
Abstract
Magnetic iron oxide nanoparticles (MNPs) have been under intense investigation for at least the last five decades as they show enormous potential for many biomedical applications, such as biomolecule separation, MRI imaging and hyperthermia. Moreover, a large area of research on these nanostructures is concerned with their use as carriers of drugs, nucleic acids, peptides and other biologically active compounds, often leading to the development of targeted therapies. The uniqueness of MNPs is due to their nanometric size and unique magnetic properties. In addition, iron ions, which, along with oxygen, are a part of the MNPs, belong to the trace elements in the body. Therefore, after digesting MNPs in lysosomes, iron ions are incorporated into the natural circulation of this element in the body, which reduces the risk of excessive storage of nanoparticles. Still, one of the key issues for the therapeutic applications of magnetic nanoparticles is their pharmacokinetics which is reflected in the circulation time of MNPs in the bloodstream. These characteristics depend on many factors, such as the size and charge of MNPs, the nature of the polymers and any molecules attached to their surface, and other. Since the pharmacokinetics depends on the resultant of the physicochemical properties of nanoparticles, research should be carried out individually for all the nanostructures designed. Almost every year there are new reports on the results of studies on the pharmacokinetics of specific magnetic nanoparticles, thus it is very important to follow the achievements on this matter. This paper reviews the latest findings in this field. The mechanism of action of the mononuclear phagocytic system and the half-lives of a wide range of nanostructures are presented. Moreover, factors affecting clearance such as hydrodynamic and core size, core morphology and coatings molecules, surface charge and technical aspects have been described.
Collapse
Affiliation(s)
- Julia Nowak-Jary
- Department of Biotechnology, Institute of Biological Sciences, University of Zielona Gora, Prof. Z. Szafrana 1, 65-516, Zielona Gora, Poland.
| | - Beata Machnicka
- Department of Biotechnology, Institute of Biological Sciences, University of Zielona Gora, Prof. Z. Szafrana 1, 65-516, Zielona Gora, Poland
| |
Collapse
|
5
|
Resealed erythrocytes: Towards a novel approach for anticancer therapy. J INDIAN CHEM SOC 2021. [DOI: 10.1016/j.jics.2021.100257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
6
|
Novel engineering: Biomimicking erythrocyte as a revolutionary platform for drugs and vaccines delivery. Eur J Pharmacol 2021; 900:174009. [PMID: 33722591 DOI: 10.1016/j.ejphar.2021.174009] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 02/25/2021] [Accepted: 02/28/2021] [Indexed: 02/07/2023]
Abstract
Over the years, extensive studies on erythrocytes, also known as red blood cells (RBCs), as a mechanism for drug delivery, have been explored mainly because the cell itself is the most abundant and has astonishing properties such as a long life span of 100-120 days, low immunogenicity, good biocompatibility, and flexibility. There are various types of RBC-based systems for drug delivery, including those that are genetically engineered, non-genetically engineered RBCs, as well as employing erythrocyte as nanocarriers for drug loading. Although promising, these systems are still in an early development stage. In this review, we aimed to highlight the development of biomimicking RBC-based drug and vaccine delivery systems, as well as the loading methods with illustrative examples. Drug-erythrocyte associations will also be discussed and highlighted in this review. We have highlighted the possibility of exploiting erythrocytes for the sustained delivery of drugs and vaccines, encapsulation of these biological agents within the erythrocyte or coupling to the surface of carrier erythrocytes, and provided insights on genetically- and non-genetically engineered erythrocytes-based strategies. Erythrocytes have been known as effective cellular carriers for therapeutic moieties for several years. Herein, we outline various loading methods that can be used to reap the benefits of these natural carriers. It has been shown that drugs and vaccines can be delivered via erythrocytes but it is important to select appropriate methods for increasing the drug encapsulated or conjugated on the surface of the erythrocyte membrane. The outlined examples will guide the selection of the most effective method as well as the impact of using erythrocytes as delivery systems for drugs and vaccines.
Collapse
|
7
|
Capossela S, Mathew V, Boos M, Bertolo A, Krupkova O, Stoyanov JV. Novel Fast and Reliable Method for Nano-Erythrosome Production Using Shear Force. Drug Des Devel Ther 2020; 14:4547-4560. [PMID: 33149552 PMCID: PMC7604965 DOI: 10.2147/dddt.s258368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 10/07/2020] [Indexed: 11/23/2022] Open
Abstract
Purpose The production of nano-erythrosomes (NEs) by extrusion, which is considered the “gold standard”, has several disadvantages such as difficult equipment assembly, long procedure time, variable pressure, and problems with sterility. An alternative approach, using ultrasound probe, has been shown to overheat the sample and have suboptimal results compared to the extrusion method. In our study, we propose, develop, and test a new method for the fabrication of NEs based on shear force and then compare it to the “gold standard” extrusion approach. Methods The new method consists of mechanical shear force disruption of the hemoglobin-depleted erythrocyte ghost membranes, with the aid of a rotor stator based tissue homogenizer. Using the same batches of erythrocyte ghost membranes, we compared NEs produced by shear force to NEs produced by the well-established extrusion approach. NEs were characterized for yield, size, encapsulation efficiency, morphology, and stability by flow cytometry (FC), transmission electron microscopy (TEM), and zeta potential analysis. Results The shear force based process was easier to set up, significantly faster, had better sterility control, and decreased variability between batches. The shear force method generated NEs with the desired size distribution (particles diameter ~125 nm), which were morphologically and functionally equivalent to the NEs produced by extrusion. NEs produced by shear force were stable in terms of counts, size, and fluorescence intensity for 3 weeks at +4°C. Moreover, they showed colloidal stability and minimal influence to centrifugal stress, turbulence shock, and hemolytic potential. Conclusion The newly proposed shear force method allows faster, easier, and highly reproducible NEs production when compared to the conventional extrusion approach. The new setup allows simultaneous production of sterile batches of NEs, which have homogenous size distribution, good stability, and improved shelf life storage. The ability of the shear force method to process also high concentration samples indicates a future potential development of large-scale NEs production and industrial application, which has been a challenge for the extrusion method.
Collapse
Affiliation(s)
- Simona Capossela
- SCI Biobanking and Translational Medicine, Swiss Paraplegic Research, Nottwil, Switzerland
| | - Vikas Mathew
- SCI Biobanking and Translational Medicine, Swiss Paraplegic Research, Nottwil, Switzerland
| | - Manuela Boos
- Institute for Biomechanics, D-HEST, ETH Zurich, Zurich, Switzerland
| | - Alessandro Bertolo
- SCI Biobanking and Translational Medicine, Swiss Paraplegic Research, Nottwil, Switzerland
| | - Olga Krupkova
- Institute for Biomechanics, D-HEST, ETH Zurich, Zurich, Switzerland.,Department of Spinal Surgery, University Hospital Basel, Basel, Switzerland.,Department of Biomedicine, University of Basel & University Hospital Basel, Basel, Switzerland
| | - Jivko V Stoyanov
- SCI Biobanking and Translational Medicine, Swiss Paraplegic Research, Nottwil, Switzerland.,Center for Applied Biotechnology and Molecular Medicine (CABMM), Zurich, Switzerland
| |
Collapse
|
8
|
Xia Q, Zhang Y, Li Z, Hou X, Feng N. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 2019; 9:675-689. [PMID: 31384529 PMCID: PMC6663920 DOI: 10.1016/j.apsb.2019.01.011] [Citation(s) in RCA: 333] [Impact Index Per Article: 66.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2018] [Revised: 10/30/2018] [Accepted: 11/28/2018] [Indexed: 12/20/2022] Open
Abstract
Erythrocytes (red blood cells, RBCs) are the most abundant circulating cells in the blood and have been widely used in drug delivery systems (DDS) because of their features of biocompatibility, biodegradability, and long circulating half-life. Accordingly, a "camouflage" comprised of erythrocyte membranes renders nanoparticles as a platform that combines the advantages of native erythrocyte membranes with those of nanomaterials. Following injection into the blood of animal models, the coated nanoparticles imitate RBCs and interact with the surroundings to achieve long-term circulation. In this review, the biomimetic platform of erythrocyte membrane-coated nano-cores is described with regard to various aspects, with particular focus placed on the coating mechanism, preparation methods, verification methods, and the latest anti-tumor applications. Finally, further functional modifications of the erythrocyte membranes and attempts to fuse the surface properties of multiple cell membranes are discussed, providing a foundation to stimulate extensive research into multifunctional nano-biomimetic systems.
Collapse
Key Words
- ABC, accelerated blood clearance
- APCs, antigen presenting cells
- Antitumor
- AuNCs, gold nanocages
- AuNPs, gold nanoparticles
- Biomimetic nanoparticles
- C8bp, C8 binding protein
- CR1, complement receptor 1
- DAF, decay accelerating factor
- DDS, drug delivery systems
- DLS, dynamic light scattering
- Dox, doxorubicin
- Drug delivery
- ECM, extracellular matrix
- EPR, enhanced permeability and retention
- ETA, endothelin A
- EpCam, epithelial cell adhesion molecule
- FA, folic acid
- GA, gambogic acid
- H&E, hematoxylin and eosin
- HRP, homologous restriction protein
- MCP, membrane cofactor protein
- MNCs, magnetic nanoclusters
- MNs, magnetic nanoparticles
- MPS, mononuclear phagocyte system
- MRI, magnetic resonance imaging
- MSNs, mesoporous silica nanoparticles
- Membrane
- NIR, near-infrared radiation
- Nanoparticles
- PAI, photoacoustic imaging
- PBS, phosphate buffered saline
- PCL, poly(caprolactone)
- PDT, photodynamic therapy
- PEG, polyethylene glycol
- PFCs, perfluorocarbons
- PLA, poly(lactide acid)
- PLGA, poly(d,l-lactide-co-glycolide)
- PPy, polypyrrole
- PS, photosensitizers
- PTT, photothermal therapy
- PTX, paclitaxel
- RBCM-NPs, RBCM-coated nanoparticles
- RBCMs, RBC membranes
- RBCs, red blood cells
- RES, reticuloendothelial system
- ROS, reactive oxygen species
- RVs, RBCM-derived vesicles
- Red blood cells
- SEM, scanning electron microscopy
- SIRPα, signal-regulatory protein alpha
- TEM, transmission electron microscopy
- TEMPO, 2,2,6,6-tetramethylpiperidin-1-yl oxyl
- TPP, triphenylphosphonium
- UCNPs, upconversion nanoparticles
- UV, ultraviolet
- rHuPH20, recombinant hyaluronidase, PH20
Collapse
Affiliation(s)
| | | | | | | | - Nianping Feng
- Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| |
Collapse
|
9
|
Tzounakas VL, Karadimas DG, Papassideri IS, Seghatchian J, Antonelou MH. Erythrocyte-based drug delivery in Transfusion Medicine: Wandering questions seeking answers. Transfus Apher Sci 2017; 56:626-634. [DOI: 10.1016/j.transci.2017.07.015] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
10
|
Singh P, Singh S, Kesharwani RK. Resealed Erythrocytes as Drug Carriers and Its Therapeutic Applications. PHARMACEUTICAL SCIENCES 2017. [DOI: 10.4018/978-1-5225-1762-7.ch018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
In this pharma innovative world, there are more than 30 drug delivery systems. Today's due to lacking the target specificity, the present scenario about drug delivery is emphasizing towards targeted drug delivery systems. Erythrocytes are the most common type of blood cells travel thousands of miles from wide to narrow pathways to deliver oxygen, drugs and nutrient during their lifetime. Red blood cells have strong and targeted potential carrier capabilities for varieties of drugs. Drug-loaded carrier erythrocytes or resealed erythrocytes are promising for various passive and active targeting. Resealed erythrocyte have advantage over several drug carrier models like biocompatibility, biodegradability without toxic products, inert intracellular environment, entrapping potential for a variety of chemicals, protection of the organism against toxic effects of the drug, able to circulate throughout the body, ideal zero-order drug-release kinetics, no undesired immune response against encapsulated drug etc. Resealed erythrocytes are rapidly taken up by macrophages of the Reticuloendothelial System (RES) of the liver, lung, and spleen of the body and hence drugs also. Resealed erythrocytes method of drugs delivery is secure and effective for drugs targeting specially for a longer period of time. This chapter will explain the different method of drug loading for resealed erythrocytes, their characterization, and applications in various therapies and associated health benefits.
Collapse
|
11
|
Rossi L, Pierigè F, Antonelli A, Bigini N, Gabucci C, Peiretti E, Magnani M. Engineering erythrocytes for the modulation of drugs' and contrasting agents' pharmacokinetics and biodistribution. Adv Drug Deliv Rev 2016; 106:73-87. [PMID: 27189231 DOI: 10.1016/j.addr.2016.05.008] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 04/29/2016] [Accepted: 05/09/2016] [Indexed: 01/14/2023]
Abstract
Pharmacokinetics, biodistribution, and biological activity are key parameters that determine the success or failure of therapeutics. Many developments intended to improve their in vivo performance, aim at modulating concentration, biodistribution, and targeting to tissues, cells or subcellular compartments. Erythrocyte-based drug delivery systems are especially efficient in maintaining active drugs in circulation, in releasing them for several weeks or in targeting drugs to selected cells. Erythrocytes can also be easily processed to entrap the desired pharmaceutical ingredients before re-infusion into the same or matched donors. These carriers are totally biocompatible, have a large capacity and could accommodate traditional chemical entities (glucocorticoids, immunossuppresants, etc.), biologics (proteins) and/or contrasting agents (dyes, nanoparticles). Carrier erythrocytes have been evaluated in thousands of infusions in humans proving treatment safety and efficacy, hence gaining interest in the management of complex pathologies (particularly in chronic treatments and when side-effects become serious issues) and in new diagnostic approaches.
Collapse
|
12
|
Leuzzi V, Rossi L, Gabucci C, Nardecchia F, Magnani M. Erythrocyte-mediated delivery of recombinant enzymes. J Inherit Metab Dis 2016; 39:519-30. [PMID: 27026098 DOI: 10.1007/s10545-016-9926-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Revised: 02/29/2016] [Accepted: 03/03/2016] [Indexed: 10/22/2022]
Abstract
The possibility to clone, express and purify recombinant enzymes have originated the opportunity to dispose of a virtually infinite array of proteins that could be used in the clinics to treat several inherited and acquired pathological conditions. However, the direct administration of these recombinant proteins faces some intrinsic difficulties, such as degradation by circulating proteases and/or inactivation by the patient immune system. The use of drug delivery systems may overcome these limitations. Concerning recombinant enzyme therapy, the present review will mainly focus on the exploitation of erythrocytes as a carrier system for enzymes removing potentially noxious metabolites from the circulation, either as limiting treatment strategy for auxotrophic tumours or as a detoxing approach for some intoxication type inherited metabolic disorders. Moreover, the possibility of using RBCs as a potential delivering system addressing the enzymes to the monocyte-macrophages of reticular endothelial system for the treatment of diseases associated with this cell lineage, e.g. lysosome storage diseases, will be briefly discussed.
Collapse
Affiliation(s)
- Vincenzo Leuzzi
- Department of Child and Adolescent Neuropsychiatry, SAPIENZA University of Rome, Via deiSabelli 108, 00185, Rome, Italy.
| | - Luigia Rossi
- Department of Biomolecular Science, University of Urbino, Via Saffi 2, 61029, Urbino, PU, Italy
| | - Claudia Gabucci
- Department of Biomolecular Science, University of Urbino, Via Saffi 2, 61029, Urbino, PU, Italy
| | - Francesca Nardecchia
- Department of Child and Adolescent Neuropsychiatry, SAPIENZA University of Rome, Via deiSabelli 108, 00185, Rome, Italy
- Department of Physiology and Pharmacology, SAPIENZA University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy
| | - Mauro Magnani
- Department of Biomolecular Science, University of Urbino, Via Saffi 2, 61029, Urbino, PU, Italy
| |
Collapse
|
13
|
Atukorale PU, Yang YS, Bekdemir A, Carney RP, Silva PJ, Watson N, Stellacci F, Irvine DJ. Influence of the glycocalyx and plasma membrane composition on amphiphilic gold nanoparticle association with erythrocytes. NANOSCALE 2015; 7:11420-32. [PMID: 26077112 PMCID: PMC6309694 DOI: 10.1039/c5nr01355k] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Erythrocytes are attractive as potential cell-based drug carriers because of their abundance and long lifespan in vivo. Existing methods for loading drug cargos into erythrocytes include hypotonic treatments, electroporation, and covalent attachment onto the membrane, all of which require ex vivo manipulation. Here, we characterized the properties of amphiphilic gold nanoparticles (amph-AuNPs), comprised of a ∼2.3 nm gold core and an amphiphilic ligand shell, which are able to embed spontaneously within erythrocyte membranes and might provide a means to load drugs into red blood cells (RBCs) directly in vivo. Particle interaction with RBC membranes occurred rapidly at physiological temperature. We further show that amph-AuNP uptake by RBCs was limited by the glycocalyx and was particularly influenced by sialic acids on cell surface proteoglycans. Using a reductionist model membrane system with synthetic lipid vesicles, we confirmed the importance of membrane fluidity and the glycocalyx in regulating amph-AuNP/membrane interactions. These results thus provide evidence for the interaction of amph-AuNPs with erythrocyte membranes and identify key membrane components that govern this interaction, providing a framework for the development of amph-AuNP-carrying erythrocyte 'pharmacytes' in vivo.
Collapse
Affiliation(s)
- Prabhani U Atukorale
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 01239, USA.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Madhavi BB, Bhavana M, Nath AR, Prasad M, Siri Vennela K. Invitro evaluation of piperine enclosed erythrocyte carriers. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.dit.2013.04.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Rahmer J, Antonelli A, Sfara C, Tiemann B, Gleich B, Magnani M, Weizenecker J, Borgert J. Nanoparticle encapsulation in red blood cells enables blood-pool magnetic particle imaging hours after injection. Phys Med Biol 2013; 58:3965-77. [PMID: 23685712 DOI: 10.1088/0031-9155/58/12/3965] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Magnetic particle imaging (MPI) is a new medical imaging approach that is based on the nonlinear magnetization response of super-paramagnetic iron oxide nanoparticles (SPIOs) injected into the blood stream. To date, real-time MPI of the bolus passage of an approved MRI SPIO contrast agent injected into the tail vein of living mice has been demonstrated. However, nanoparticles are rapidly removed from the blood stream by the mononuclear phagocyte system. Therefore, imaging applications for long-term monitoring require the repeated administration of bolus injections, which complicates quantitative comparisons due to the temporal variations in concentration. Encapsulation of SPIOs into red blood cells (RBCs) has been suggested to increase the blood circulation time of nanoparticles. This work presents first evidence that SPIO-loaded RBCs can be imaged in the blood pool of mice several hours after injection using MPI. This finding is supported by magnetic particle spectroscopy performed to quantify the iron concentration in blood samples extracted from the mice 3 and 24 h after injection of SPIO-loaded RBCs. Based on these results, new MPI applications can be envisioned, such as permanent 3D real-time visualization of the vessel tree during interventional procedures, bleeding monitoring after stroke, or long-term monitoring and treatment control of cardiovascular diseases.
Collapse
Affiliation(s)
- J Rahmer
- Philips Technologie GmbH Innovative Technologies, Research Laboratories, Röntgenstrasse 24-26, D-22315 Hamburg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Herein recent progress in developing red blood cell (RBC)-inspired delivery systems is reviewed, with an emphasis on how our growing understanding of fundamental biological properties of natural RBCs has been applied in the design and engineering of these delivery systems. Specifically, progress achieved in developing carrier RBCs, a class of delivery vehicles engineered by directly loading natural RBCs with therapeutic agents, will be reviewed. Then alternative approaches to engineering synthetic vehicles through mimicking the mechanobiological and chemico-biological properties of natural RBCs will be considered. The synthesis and application of RBC membrane-derived vesicles, of which the natural RBC membranes are collected and directly utilized to prepare drug carriers, will then be discussed. Finally, a recent approach in engineering RBC membrane-camouflaged nanoparticle systems that combine advantages of natural RBCs and synthetic biomaterials will be highlighted. These developments indicate that RBC-inspired delivery systems will result in next-generation nanomedicine with extensive medical applications.
Collapse
Affiliation(s)
- Che-Ming J Hu
- Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
| | | | | |
Collapse
|
17
|
Engineering erythrocytes to be erythrosensors: first steps. Blood Cells Mol Dis 2012; 47:100-6. [PMID: 21641241 DOI: 10.1016/j.bcmd.2011.05.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2011] [Accepted: 05/06/2011] [Indexed: 11/23/2022]
Abstract
Molecules can be loaded into mammalian erythrocytes through a reversible lysis pore that forms in the membrane when placed in hypotonic media, the result being resealed red cell ghosts. Many studies on the sidedness of transport processes have utilized this approach. In addition, red cell ghosts encapsulated with enzymes have been used in patients to treat specific enzyme deficiencies, particularly when the substrate can cross the red cell membrane. Our long-term goal is to put fluorescent sensors inside erythrocytes, return the loaded red cell ghosts to the animal or patient, and then monitor the fluorescence non-invasively to follow changes in plasma analyte concentration. In this paper, we present a novel dialysis method for making the red cell ghosts. In addition, we present a theoretical analysis showing that it is not necessary that every loaded red cell ghost has the same dye concentration. Finally we discuss the constraints on the optimal affinity for the sensor/analyte interaction.
Collapse
|
18
|
Ritter SC, Milanick MA, Meissner KE. Encapsulation of FITC to monitor extracellular pH: a step towards the development of red blood cells as circulating blood analyte biosensors. BIOMEDICAL OPTICS EXPRESS 2011; 2:2012-2021. [PMID: 21750776 PMCID: PMC3130585 DOI: 10.1364/boe.2.002012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2011] [Revised: 06/17/2011] [Accepted: 06/17/2011] [Indexed: 05/29/2023]
Abstract
A need exists for a long-term, minimally-invasive system to monitor blood analytes. For certain analytes, such as glucose in the case of diabetics, a continuous system would help reduce complications. Current methods suffer significant drawbacks, such as low patient compliance for the finger stick test or short lifetime (i.e., 3-7 days) and required calibrations for continuous glucose monitors. Red blood cells (RBCs) are potential biocompatible carriers of sensing assays for long-term monitoring. We demonstrate that RBCs can be loaded with an analyte-sensitive fluorescent dye. In the current study, FITC, a pH-sensitive fluorescent dye, is encapsulated within resealed red cell ghosts. Intracellular FITC reports on extracellular pH: fluorescence intensity increases as extracellular pH increases because the RBC rapidly equilibrates to the pH of the external environment through the chloride-bicarbonate exchanger. The resealed ghost sensors exhibit an excellent ability to reversibly track pH over the physiological pH range with a resolution down to 0.014 pH unit. Dye loading efficiency varies from 30% to 80%. Although complete loading is ideal, it is not necessary, as the fluorescence signal is an integration of all resealed ghosts within the excitation volume. The resealed ghosts could serve as a long-term (>1 to 2 months), continuous, circulating biosensor for the management of diseases, such as diabetes.
Collapse
Affiliation(s)
- Sarah C. Ritter
- Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA
| | - Mark A. Milanick
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
| | - Kenith E. Meissner
- Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA
| |
Collapse
|
19
|
Palmitic acid induces the opening of a Ca2+-dependent pore in the plasma membrane of red blood cells: the possible role of the pore in erythrocyte lysis. J Membr Biol 2010; 237:13-9. [PMID: 20835705 DOI: 10.1007/s00232-010-9302-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2010] [Accepted: 08/17/2010] [Indexed: 12/27/2022]
Abstract
Earlier we found that in the presence of Ca(2+) palmitic acid (Pal) increases the nonspecific permeability of artificial (planar and liposomal) membranes and causes permeabilization of the inner mitochondrial membrane. An assumption was made that the mechanism of Pal/Ca(2+)-induced membrane permeabilization relates to the Ca(2+)-induced phase separation of Pal and can be considered as formation of fast-tightening lipid pores due to chemotropic phase transition in the lipid bilayer. In this article, we continue studying this pore. We have found that Pal plus Ca(2+) permeabilize the plasma membrane of red blood cells in a dose-dependent manner. The same picture has been revealed for stearic acid (20 μM) but not for myristic and linoleic acids. The Pal-induced permeabilization of erythrocytic membranes can also occur in the presence of Ba(2+) and Mn(2+) (200 μM), but other bivalent cations (200 μM Mg(2+), Sr(2+), Ni(2+), Co(2+)) are relatively ineffective. The formation of Pal/Ca(2+)-induced pores in the erythrocytic membranes has been found to result in the destruction of cells.
Collapse
|
20
|
Patent Briefing. J Microencapsul 2008. [DOI: 10.3109/02652048809064171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
21
|
Literature Alerts. J Microencapsul 2008. [DOI: 10.3109/02652048809064172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
22
|
Baysal SH, Uslan AH, Pala HH, Tunçoku O. Encapsulation of PEG-urease/PEG-AlaDH within sheep erythrocytes and determination of the system's activity in lowering blood levels of urea in animal models. ACTA ACUST UNITED AC 2007; 35:391-403. [PMID: 17701485 DOI: 10.1080/10731190701460259] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Urease and AlaDH enzymes immobilized on active PEG derivatives were encapsulated at different ratios within sheep erythrocytes and their activity, encapsulation yields and erythrocyte recovery levels were assessed. Encapsulated derivatives were administered at given dosages and at given intervals to sheep having raised blood urea levels as a result of addition of urea to their feed, and the lowering of their blood urea levels and the change in the amount of ammonia were followed. Results were analyzed using day related NPar. Wilcoxon Signet Ranks test. It was found that 1 ml of PEG-enzyme preparation comprising PEG-urease/PEG-AlaDH at an activity ratio of 3/9 U:U/ml remained active for a period of 2 days, whereas 1 ml erythrocyte preparation, prepared under the same conditions and containing PEG-urease/PEG-AlaDH at an activity ratio of 2.15/4.5 U:U/ml, showed activity for a period of 6 days. It was shown that a single dose achieved a daily decrease of 21.7-61.6 mg/L in the blood urea level, and created no significant increase in the blood ammonia levels. No antigenic effect was observed for the PEG-enzyme preparations in the immunological test carried out.
Collapse
|
23
|
Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 2006; 118:145-60. [PMID: 17270305 DOI: 10.1016/j.jconrel.2006.06.032] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2006] [Accepted: 06/20/2006] [Indexed: 11/25/2022]
Abstract
Carrier erythrocytes, resealed erythrocytes loaded by a drug or other therapeutic agents, have been exploited extensively in recent years for both temporally and spatially controlled delivery of a wide variety of drugs and other bioactive agents owing to their remarkable degree of biocompatibility, biodegradability and a series of other potential advantages. Biopharmaceuticals, therapeutically significant peptides and proteins, nucleic acid-based biologicals, antigens and vaccines, are among the recently focused pharmaceuticals for being delivered using carrier erythrocytes. In this article, the potential applications of erythrocytes in drug delivery have been reviewed with a particular stress on the studies and laboratory experiences on successful erythrocyte loading and characterization of the different classes of biopharmaceuticals.
Collapse
Affiliation(s)
- Mehrdad Hamidi
- Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, P.O. BOX 71345-1583, Shiraz, Iran.
| | | | | | | |
Collapse
|
24
|
Baysal SH, Uslan AH. Encapsulation of Urease and PEG-Urease in erythrocyte. ARTIFICIAL CELLS, BLOOD SUBSTITUTES, AND IMMOBILIZATION BIOTECHNOLOGY 2000; 28:263-71. [PMID: 10852677 DOI: 10.3109/10731190009119357] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Erythrocytes can be used to entrap drugs, enzymes or other molecules with active properties, with various encapsulation procedures. The carrier is nonimmunogenic, biodegradable, and circulates freely throughout the body. Urease was covalently immobilized on activated methoxypolyethyleneglycol-5000 (PEG-5000) (1:3 molar ratio). Urease and PEG-Urease were encapsulated in erythrocyte (1/1) (v/v) by using slow dialysis methods. To optimize the loading of erythrocyte, the above base procedure was varied to test the effect of some parameters. Dialysis time, dialysis temperature, storage condition for erythrocyte conjugate, Urease and PEG-Urease concentration were investigated.
Collapse
Affiliation(s)
- S H Baysal
- Ege University, Faculty of Science, Biochemistry Department, Bornova-Izmir, Turkiye
| | | |
Collapse
|
25
|
Harrison M, Isaacson C, Rathinavelu P, Low PS. Resealing of protein tyrosine kinase substrates into human erythrocytes by rapid freezing and thawing in liquid nitrogen. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1992; 326:111-7. [PMID: 1295296 DOI: 10.1007/978-1-4615-3030-5_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- M Harrison
- Department of Medicinal Chemistry and Pharmacognosy, Purdue University, West Lafayette, Indiana
| | | | | | | |
Collapse
|
26
|
Zolla L, Lupidi G, Marcheggiani M, Falcioni G, Brunori M. Encapsulation of proteins into human erythrocytes: a kinetic investigation. BIOCHIMICA ET BIOPHYSICA ACTA 1990; 1024:5-9. [PMID: 2337620 DOI: 10.1016/0005-2736(90)90202-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Moderate osmotic shocks of human erythrocytes by hypotonic dialysis (0.06 mosmol/kg) induce cell swelling and formation of pores, without causing apparent lysis. Using 125I-labeled macromolecules of different molecular weight and net charge, we followed the kinetics and efficiency of their encapsulation into erythrocytes. After a 20-30 min period of cell dialysis, macromolecules of up to 50 kDa begin diffusing into the swollen cells by a process which can be described by a first-order two-compartment kinetics. Adsorption to the external cell surface was insignificant, while adsorption to the inner membrane surface was substantial (15-20%) only for positively charged proteins, at physiological pH. After resealing, pores of a 12-14 kDa cut-off might remain open allowing some release of entrapped material (20-30%), depending on the final cytocrit, while the remaining might be associated with inner membrane or cytosolic components. Although the method of hypotonic dialysis is known to affect minimally the biophysical and immunological properties of red blood cell membranes, the interaction of encapsulated material with cell constituents would need to be further assessed when considering red cells as macromolecular carriers.
Collapse
Affiliation(s)
- L Zolla
- Department of Cell Biology, University of Camerino, Italy
| | | | | | | | | |
Collapse
|